No profile data available.
Opus Genetics, Inc. (IRD) is a healthcare company in the eye treatment pharmaceuticals industry, based in Durham, United States, with about 18 full-time employees.
It reported revenue of $14.20 million for fiscal year 2025, up 29.1% from fiscal year 2024, and net income of -$49.59 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $755,000, down 73.8% from a year before. Its market capitalization was $153.79 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Opus Genetics reported $14.20 million in revenue for fiscal year 2025, up 29.1% from $10.99 million in fiscal year 2024. In Q2 2026 revenue was $755,000.
$153.79 million as of December 4, 2025.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Ocugen, Inc. (OCGN), EyePoint Pharmaceuticals, Inc. (EYPT), Lineage Cell Therapeutics, Inc. (LCTX), Outlook Therapeutics, Inc. (OTLK).